1. Home
  2. CLRO vs CALC Comparison

CLRO vs CALC Comparison

Compare CLRO & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearOne Inc. (DE)

CLRO

ClearOne Inc. (DE)

SELL

Current Price

$4.76

Market Cap

8.7M

Sector

Technology

ML Signal

SELL

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

SELL

Current Price

$1.18

Market Cap

7.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CLRO
CALC
Founded
1983
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7M
7.6M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
CLRO
CALC
Price
$4.76
$1.18
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $42.00
AVG Volume (30 Days)
★ 6.4M
65.5K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $46,067,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 11.59
N/A
52 Week Low
$1.62
$0.44
52 Week High
$16.50
$72.00

Technical Indicators

Market Signals
Indicator
CLRO
CALC
Relative Strength Index (RSI) 53.90 39.19
Support Level $3.32 $1.08
Resistance Level $5.91 $1.84
Average True Range (ATR) 0.87 0.23
MACD -0.05 0.01
Stochastic Oscillator 37.91 3.27

Price Performance

Historical Comparison
CLRO
CALC

About CLRO ClearOne Inc. (DE)

ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: